21
The FDA accepted a supplemental biologics license application for dupilumab (Dupixent) for priority review to treat adults with bullous pemphigoid.1
Currently, treatment aims to stop the development of new lesions and facilitate control and healing of lesions. | Image Credit: peterschreiber.media | stock.adobe.com
Bullous pemphigoid is an autoimmune blistering disease that is caused by the “presence of autoantibodies directed against specific adhesion molecules of the skin and mucous membranes,” according to a review published in The Lancet.2 The condition is the most common of this type of disease and occurs commonly in elderly patients. The…